News

The NIDA director reviews neuromodulation's potential role in treating patients with multiple use disorders, and the importance of patient feedback in shaping clinical research.

Rachel Talley, MD, discusses the industry-level changes needed to trainee recruitment and retention to create a psychiatry field more representative of its patient population.

Rates per 100 person-years for adverse events, infections, and major adverse cardiac events were similar between placebo and ustekinumab through up to 5 years.

The age of screening for colon cancer has decreased in recent years.

Dr. Dubinsky said new IL-23 treatments could enable precision medicine in the future for IBD.

The findings show EUS-CDL is more efficient than ERCP-M with comparable short-term effectiveness and safety.

New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.

Data show the presence of five and six risk factors increased the risk of VTE exponentially to 10.9% and 25%, respectively

The treatment recently became the first ever FDA-approved medication for EoE.

Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders.

With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.

This approval makes tapinarof cream the first and only FDA-approved steroid-free topical medication in its class.

Despite this, more than half of nurses included in this global survey were not financially compensated for their additional work.

Brent Forester, MD, MSc, discusses the confluence of biomarker and disease-targeting therapy in Alzheimer's, and the need to appropriately introduce these tools.

Clinicians give their opinions on patient-reported outcome measures regarding both initial diagnosis and management of patients with rheumatic disease.

New research has suggested that approximately 2%-5% of patients with sarcoidosis also struggle with cardiac sarcoidosis.

The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.

Dementia and Alzheimer's disease cases are anticipated to boom in coming decades. One expert stressed the need for improved screening and facilitation of care at the earliest stages and signs.

Data show the proportion of individuals with sustained clinical cure through Week 8 was 80.3% with CP101 treatment.

Initial studies have shown a 73% efficacy for FMT in treating patients with HVGD.

BMI did not have an association with increased risk for death in any BMI category, according to study investigators.

A look into the efficacy of ozanimod in patients with UC and the potential risk for cardiovascular events.

The live microbiota therapeutic has shown promise in treating patients with recurrent CDI.

In a late-breaking presentation at ASGCT 2022, investigators shared preclinical results of a gene-editing strategy that seeks to reactivate developmentally silenced fetal hemoglobin (HbF, α2γ2) in order to replace defective sickle hemoglobin (HbS, α2βS2).

Patients who have IPAA are more than twice as likely to suffer from male sexual dysfunction.

James Woody, MD, PhD, explains the benefits of treating Dupuytren’s disease with anti-tumor necrosis factor (TNF).

Data from 2 studies evaluating adults with active psoriatic arthritis were announced today in preparation for EULAR 2022. The different population groups who received treatment were biologic-naive patients and TNF-inadequate responders.

Patients treated with TNF- antagonists had a higher deep remission rate compared to patients treated with ustekinumab.

Patients with IBD are often at an increased risk of developing NAFLD.